The global intranasal drug and vaccine delivery market was valued at USD 47,980.8 million in 2019. Rise in intranasal product launches and increasing prevalence of respiratory as well as neurological diseases has sparked a surge in demand for intranasal drug and vaccine delivery market. As a result of easy administration and better efficacy, the patient preference for nasal drug delivery has increased and the rise in demand for home healthcare devices worldwide are certain factors that are propelling the growth of the global intranasal drug and vaccine delivery market.
Depending on the optimal remedial methodology for the patients, intranasal medicate conveyance frameworks monitor sedates by nasal course for nearby or fundamental operation. For extreme or ceaseless drugs, nasal medications can be prescribed and include anti-microbials, snuffs, vasoconstrictors, neighborhood soporifics, aid with medications for pain, calcium enhancements, antihistamines and others. These drugs, such as nasal splashes, balms and arrangements, are handled in a few dosage systems. Competitors of medicine with impaired oral intake and provided with a first-pass effect in the body are preferred in detailing the conveyance of nasal medicine. The nasal vaccination route could also provide protection at many distant mucosal sites (oral, rectal, vaginal, and pulmonary), which is considered to be a simpler and cost-effective, patient-compliant mode of vaccination. Some delivery systems for nasal vaccines in the form of microparticulates, nanoparticulates and liposomes are currently being developed and have been shown to provide immunity in animal models.
The market growth is primarily driven by the growing acceptance of non-invasive treatments. The market for intranasal medication and vaccine delivery devices is growing in the number of prescriptions for non-invasive drug delivery routes for the treatment of chronic diseases, such as rhinitis, asthma, migraine, and other CNS diseases. According to the International Study of Asthma and Allergies in Childhood (ISAAC) reported in the 2018 World Allergy Organization Report, the incidence of allergic rhinitis is about 0.8% and 14.9% in the age group of 6-7 years and 1.4% in the age group of 13-14 years globally. This is anticipated to boost the growth of intranasal drug and vaccine delivery market during the forecast period.
Key players operating in the global intranasal drug and vaccine delivery market include GlaxoSmithKline Plc, Teva Pharmaceuticals, Aptar Pharma, UCB, Inc., Teleflex Corporation, 3M, Bespak, OptiNose, Inc., and Intersect ENT, among others.
Key Segments of the Global Intranasal Drug and Vaccine Delivery Market
Product Type Overview, 2018-2028 (USD Million)
- Powder Delivery Device
- Liquid Delivery Device
- Pressurized Metered Dose Inhaler
Dosage Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
- Respiratory Disorders
- Neurological Disorder
- Pain Management
Distribution Channel Overview, 2018-2028 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
Reasons for the study
- Increasing patient preference for nasal drug and vaccine delivery as a result of easy administration and better efficacy
- Growing adoption of self-administration practices
- Rise in demand for home healthcare devices
What does the report include?
- The study on the global intranasal drug and vaccine delivery market includes qualitative insights such as drivers, restraints, challenges and opportunities
- Additionally, the market has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of product type, dosage, application, and distribution channel. Moreover, the study on intranasal drug and vaccine delivery market provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players operating in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global intranasal drug and vaccine delivery market is suitable for all the players across the value chain including raw medical material suppliers, respiratory disorders, long-term care facilities, neurosurgeon’s vaccination, neurological disorder, medical device manufacturers, healthcare organizations, distributors, suppliers and wound type geeks
- Venture capitalists and investors looking for more information on the future outlook of the global intranasal drug and vaccine delivery market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global intranasal drug and vaccine delivery market
The need for intranasal drug and vaccine delivery has significantly increased owing to the increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy. The delivery of drugs via nasal route is considered as one of the most favoured drug delivery methods by patients as well as by healthcare providers. This is due to the non-invasive nature of the delivery of the drug and better drug absorption via the nasal route. Furthermore, compared to the other routes, the nasal path offers a less aggressive environment and this allows better drug absorption. Hence, this is likely to flourish the demand for intranasal drug and vaccine delivery during the forecast period.
In addition, due to the growing patient compliance, this has led to growing technical developments related to nasal drug delivery systems. For example, there is increasing clinical support for the treatment of central nervous system disorders by administrating drugs through the nasal route. Also, at higher concentrations, the nasal route will cross the blood-brain barrier. This offers better options for treating patients suffering from CNS conditions without needles. However, moderate complications and side effects associated with the use of nasal products can impede the growth of the global market.
Furthermore, as different nasal drug delivery technologies for the administration of COVID-19 vaccines are under development by market players, the market is expected to gain traction over the forecast period. For example, Bharat Biotech initiated clinical trials for the COVID-19 nasal drop vaccine on 7 April 2020. The group has partnered with vaccine manufacturer FluGen and the University of Wisconsin-Madison to conduct clinical trials in the United States. Thus, this will further boost the intranasal drug and vaccine delivery market.
The global intranasal drug and vaccine delivery market has been segmented based on product type, dosage, application, distribution channel and region. Based on product type, the intranasal drug and vaccine delivery market is segmented into powder delivery device, liquid delivery device, pressurized metered dose inhaler and others wherein the liquid delivery device segment dominated the market. Various formulations, such as aqueous solutions, emulsions, and suspensions, are available. It is anticipated that regular developments and the launch of novel devices for different indications would boost segment growth. In March 2019, for example, Aptar Pharma, a supplier of drug delivery systems, earned the U.S. FDA approval for the nasal spray system Bidose.
On the basis of dosage, the intranasal drug and vaccine delivery market is segmented into unit-dose, and multi-dose. The Multi-dose spray pumps segment dominated the market as they provide patients suffering from chronic diseases, such as allergic rhinitis, with a cost-effective, easy and safe alternative.
Based on application, the intranasal drug and vaccine delivery market is segmented into respiratory disorders, neurological disorder, vaccination, pain management, and others. The respiratory disorders segment dominated the market in 2019 due to the use of intranasal devices such as asthma, nasal inflammation, and allergic rhinitis to treat a number of respiratory disorders.
Based on distribution channel, the intranasal drug and vaccine delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail segment dominated the market due to the growing awareness of patients, self-administration, and increasing concentration on positive medical results. In addition, software developers work in partnership with different pharmacy chains to make various point-of- care drugs available without prescription.
The global intranasal drug and vaccine delivery market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global intranasal drug and vaccine delivery market in 2019, however Asia Pacific is expected to grow at a highest pace through 2028.
North America, especially the U.S. dominates the global intranasal drug and vaccine delivery market. This is due to the increasing prevalence of asthma and chronic obstructive pulmonary disease and the increasing acceptance of early treatment procedures. As well as it is attributed to advanced technology, product launches and creativity. As the third leading cause of death in the United States is found to be chronic obstructive pulmonary disease, the rising prevalence of COPD can therefore help to increase the adoption of intranasal drug and vaccine delivery devices.
Asia Pacific is expected to be the fastest growing regional market for intranasal drug and vaccine delivery owing to factors such as the existence of a large patient base, growing medical tourism, rising healthcare spending by the government, and acceptance of non-invasive treatments. In addition, it is also due to the availability of efficient care options, high clinical needs that are not met, growing levels of disposable income and increasing awareness of these items.